8-KLeadership ChangesRegulation FDExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Executive Changes (Oct 30, 2025)

Filed October 30, 2025For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) announced a significant leadership change via an 8-K filing on October 30, 2025. Chief Financial Officer (CFO) Scott Ullem has informed the company of his decision to transition out of his role by mid-2026. This development triggers an active search for a successor to lead the company's financial strategy. While the departure is planned for mid-2026, the immediate focus for investors is the initiation of the CFO selection process. This transition, though not immediate, is a key event that warrants attention as the company navigates its financial future. Investors will be keen to understand the timeline for appointing a new CFO and the potential impact on the company's financial management and strategic direction.

Key Highlights

  • 1CFO Scott Ullem has decided to transition from his role by mid-year 2026.
  • 2Edwards Lifesciences has initiated a formal selection process to appoint a new Chief Financial Officer.
  • 3The announcement was made on October 30, 2025, through an 8-K filing and a press release.
  • 4The departure is planned for mid-2026, indicating a phased transition.
  • 5The company is seeking to ensure a smooth handover of financial leadership responsibilities.

Frequently Asked Questions

Scott Ullem is expected to transition from his role as Chief Financial Officer by mid-year 2026.

Edwards Lifesciences has initiated a selection process to appoint a new Chief Financial Officer.

No, the departure is not immediate. Scott Ullem plans to transition by mid-year 2026, allowing for a planned succession.

This announcement signals a change in financial leadership. Investors will monitor the CFO selection process and the individual appointed to ensure continuity and effective financial strategy moving forward.